May 9, 2001
Taisho Announces Release of White Iris Eyedrops for Women:
Taisho Pharmaceutical Co., Ltd. (president: Akira Uehara) will release White Iris eyedrops, which relieve bloodshot eyes while at the same time fighting the cause, on May 10. White Iris will sell in 7ml bottles for 780 yen.
Taisho incorporated ocular research into its development of White Iris, combined with a fast-acting solution for unsightly red lines. The active ingredient of the drops is tetrahydrozoline HCL, which has earned a reputation for delivering effective relief from bloodshot eyes. Eyes become bloodshot when they are not receiving enough nutrients. Capillaries in the cornea expand to compensate for the lack of nutrients, thus creating the spidery red lines. White Iris provides the necessary nutrient supplements with a combination of amino acid (taurin) and vitamin B6. The drops provide effective relief by both controlling the causes and treating the effects of bloodshot eyes.
A Taisho marketing survey indicated that 80 percent of eyedrops users rely on drops to relieve bloodshot eyes. The market for eyedrops targeting female users has grown by 150 percent over the past 5 years, and is expected to continue expanding as more women in their 20s and 30s remain in the workforce. In attempting to develop an all-purpose eye treatment product, Taisho succeeded in creating White Iris, a solution that meets the needs of these working women.
| Product Features